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The overall objective of this research is to examine the joint effect of multiple variants 
in folate metabolism on CVD outcome. The intermediary outcome, homocysteine, will 
be investigated as the primary endpoint because the metabolic disruption characterized 
by elevated homocysteine levels is proposed to mediate the risk of CVD. Because 
epidemiologic studies are limited by small sample size, and thus reduced statistical 
power to examine genetic interactions and their combined effects on disease outcome, 
we utilize computer simulations to study five SNPs in four candidate genes that code 
for enzymes that are all linked through sequential metabolic steps in homocysteine 
remethylation. These enzymes are either directly involved in homocysteine 
remethylation or indirectly linked because they provide essential substrates required 
for the conversion of homocysteine to methionine by MTR. Using MTR as our focal 
point, we also considered gene-nutrient interactions among the five variants and 
varying levels of folate and vitamin B12 to account for the possible effects of 
nutritional status on disease risk. This approach led to the key finding that having 
double variants for all possible polymorphisms in a pathway does not necessarily 
equate to the most deleterious effects, and that only vitamin B12 had an effect on the 
homocysteine levels as a nutrient cofactor. Our simulations also illustrate how 
pathways have built-in regulatory mechanisms that researchers might not be able to 
account for when taking a single candidate gene approach to studying disease 
 outcome. We anticipate that our model will serve as an example of how simulations 
can help advance the growing idea that disease treatment can be personalized by 
examining an individual’s unique genetic and nutritional profile. 
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CHAPTER 1 
THEORETICAL MOTIVATION FOR COMPLEX SYSTEMS MODELING OF 
METABOLIC PATHWAYS 
A. FOLATE METABOLISM AND CARDIOVASCULAR DISEASE 
Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of adult morbidity and 
mortality worldwide, and is expected to remain as the primary cause of death through 
the year 2030 (1-2). The most common forms of CVD are multifactorial in origin, 
resulting from single or many genes working in combination with other genes (i.e. 
gene-gene interactions) and/or environmental factors to produce CVD risk (3). 
Monogenetic CVD can also arise due to a single genetic mutation in one of three 
genes involved in lipoprotein synthesis, but such incidences are rare (3-5).  “Classical” 
risk factors for CVD are age, male gender, family history of premature CVD, cigarette 
smoking, hypertension, lipid abnormalities, diabetes mellitus, physical inactivity, poor 
diet, alcohol intake and obesity (6). Recently, other risk markers thought to play a 
causal role in CVD development have been identified, including biochemical 
indicators such as elevated plasma homocysteine (7). 
Homocysteine: a biomarker for CVD 
Homocysteine is a sulfur amino acid that forms as a result of S-
adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) demethylating the 
essential amino acid methionine (8). Total plasma homocysteine, which refers to all 
forms of homocysteine in plasma (i.e., free form or protein-bound (majority)), can be 
metabolized via two separate pathways: the irreversible transsulfuration pathway and 
the homocysteine remethylation pathway; the latter predominates under normal 
physiological conditions (9-10) (Figure 1.1).  
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Figure 1.1: Overview of Homocysteine Metabolism 
Major enzymes, nutrient cofactors and their roles in homocysteine remethylation: 
MAT = methionine adenosyltransferase; MT = methyltransferases; SAHH = S-
adenosylhomocysteine hydrolase; BHMT = betaine-homocysteine methyltransferase; 
MTHFD = methylenetetrahydrofolate dehydrogenase; SHMT = serine 
hydroxymethyltransferase; CBS = cystathionine beta-synthase; C = gama-
cystathionase; MTR = methionine synthase; MTHFR = methylenetetrahydrofolate 
reductase; THF = tetrahydrofolate; B2, B6, B12 = vitamins B2, B6, B12 , respectively. 
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Degradation of intracellular homocysteine to cysteine through the 
transsulfuration pathway is limited to liver and kidney cells and involves cystathionine 
beta-synthase (CBS) and γ-cystathionase, enzymes that both require pyridoxal 5’-
phosphate (PLP; vitamin B6) as a cofactor while homocysteine remethylation occurs 
through two unique enzymatic reactions involving either methionine synthase (MTR) 
with 5-methyltetrahydrofolate (5-methylTHF) as the methyl donor or betaine-
homocysteine methyltransferase (BHMT) with betaine as the donor of one-carbon 
units. Remethylation by BHMT is restricted to liver and kidney cells while 
remethylation by MTR can occur in every cell except red blood cells (8-10). The 
primary focus of this research is directed towards understanding the role of key factors 
involved in homocysteine remethylation through the MTR pathway where MTR is the 
major transmethylase (Figure 1.2). 
 
 
Figure 1.2: Homocysteine Remethylation through the MTR pathway 
MTHFD = methylenetetrahydrofolate dehydrogenase; SHMT = serine 
hydroxymethyltransferase; MTR = methionine synthase; MTHFR = 
methylenetetrahydrofolate reductase; THF = tetrahydrofolate 
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Epidemiology of CVD  
Studies taking the traditional reductionist approach have concluded that 
disruption of normal enzymatic function within the homocysteine remethylation 
pathway through MTR can result in an accumulation of homocysteine, leading to 
increased CVD risk. Meta-analyses of epidemiologic studies have found that total 
plasma homocysteine is an independent predictor of CVD (11-12). Results from a 
meta-analysis conducted in 2002 of prospective studies estimated that a decrease in 
total plasma homocysteine of 3umol/L was associated with a 16% decrease in heart 
disease (12). Similarly, a meta-analysis by the Homocysteine Studies Collaboration 
that included studies published between January 1966 and January 1999 reported that 
a 25% lower than usual homocysteine level (~3 umol/L; 0.41mg/L) was associated 
with an 11% lower risk of ischemic heart disease (OR= 0.89; 95% CI: 0.83-0.96) (11). 
The mechanisms by which elevated homocysteine affects CVD risk are not completely 
specified, but it has been hypothesized that elevated homocysteine concentrations 
cause: (a) endothelial dysfunction by impairing nitric oxide synthesis (b) platelet 
activation, (c) a pro-inflammatory response by inducing production of tumor necrosis 
factor-alpha and (d) accelerated oxidation of low-density lipoproteins (LDL), and thus, 
atherosclerosis (6,7,10-11, 13-24). The proposed mechanisms by which homocysteine 
increases CVD risk support epidemiologic findings that report an association between 
increased blood homocysteine concentrations among individuals with vascular 
disease, where elevated homocysteine levels precede CVD onset (25-29).   
Genetic and Nutritional Determinants of Homocysteine Remethylation and CVD Risk 
The homocysteine remethylation pathway via MTR is embedded within the 
larger one-carbon folate metabolic pathway (Figure 1.3). Studies have demonstrated 
an association between increased blood homocysteine concentrations and changes in 
individual states of oxidation as well as the addition or removal of one-carbon groups 
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like folate (30). MTR, a vitamin B12-dependent enzyme, catalyzes the methyl group 
transfer from 5-methylTHF to homocysteine, resulting in methionine and THF (31). 
The proper functioning of this enzyme is critical for ensuring that homocysteine levels 
do not reach toxic levels. It is, thus, biologically plausible that inadequate levels of 
vitamin B12 or disruption in MTR function can affect MTR activity level, which in 
turn can lead to hyperhomocysteinemia as well as homocysteinuria (32). 
 
Figure 1.3: Global Folate Metabolic Network, adapted from Stipanuk et al. (33) 
These are the major folate-dependent one carbon metabolic pathways in the cytoplasm 
of the cell. AICAR: 5-amino-4-imidazolecarboxamid ribonucleotide; AICART: 
AICAR formyltransferase; CYH: methenyltetrahydrofolate cyclohydrolase; DHFR: 
dihydrofolate reductase; dTMP: 2-deoxythymidine 5’-monophosphate; dUMP: 2-
deoxyuridine 5’-monophosphate; GAR: glycinamide ribonucleotide; GART: GAR 
formyltransferase; MS (MTR): methionine synthase; MTHFD: 
methylenetetrahydrofolate dehydrogenase; MTHFR methylenetetrahydrofolate 
reductase; (c)SHMT: cytoplasmic serine hydroxymethyltransferase; TS: thymidylate 
synthase. 
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A common single nucleotide polymorphism (SNP) in MTR consists of an A-to-
G nucleotide substitution at base pair 2756 (rs1805087), leading to an amino acid 
change from aspartic acid to glycine at codon 919 (34). Functional consequences of 
this mutation have not been clearly established, and the influence of the MTR 2756 
AG polymorphism on total plasma homocysteine levels is still a matter of debate. 
Some studies suggest that individuals with MTR 2756 AA genotype have lower 
homocysteine concentrations (compared to those with MTR 2756 GG genotype), 
implying an increased level of enzymatic activity in the presence of the variant 
genotype (35-38). Other studies have reported either no functional differences (39-42) 
or an increase in homocysteine concentration as a result of the MTR 2756 AG 
polymorphism (37, 43). In laboratory studies, complete loss of MTR activity in mice 
has been linked to early embryonic lethality (44). Similarly, severe clinical 
consequences have been observed in humans lacking MTR activity (45).  
With regard to nutrient cofactors, traditional gene association studies 
hypothesize that the MTR 2756 AG polymorphism may decrease the ability of 
vitamin B12 to bind to its receptor site on MTR, in part because the SNP is in close 
proximity to the vitamin B12 binding domain of the protein. The role of vitamin B12 
as a cofactor is critical for proper MTR function because it serves as an intermediary 
in methyl transfers catalyzed by MTR (46). Thus, the SNP is hypothesized to increase 
the risk of CVD (less remethylation of homocysteine) as well as increase cellular B12 
levels (less binding of B12 to enzyme). With respect to plasma vitamin B12 levels, 
prior work has shown that reduced levels of plasma vitamin B12 are associated with 
higher homocysteine levels and thus, greater CVD risk (47). Typically about 20% of 
total circulating vitamin B12 is carried by transcobalamin 2, which is responsible for 
transporting vitamin B12 in the blood to the cell, and a reduction in total circulating 
vitamin B12 levels will proportionally reduce the availability of vitamin B12 to bind 
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to transcobalamin 2, causing a deficit in vitamin B12 availability for MTR to use as a 
cofactor to remethylate homocysteine. Studies examining the association of MTR 2756 
AG with circulating vitamin B12 levels have produced mixed results: some report 
no association between MTR 2756 AG genotype and blood vitamin B12 levels (37, 
41, 48-49) and others report a decrease of ~30% in serum vitamin B12 levels by MTR 
2756 AG genotype (MTR 2756 GG vs. MTR 2756 AA/AG) (40, 50).  To the best of 
our knowledge, whether the effect of the polymorphism on cardiovascular disease risk 
varies by nutritional status of vitamin B12 has not been studied to date. However, 
results from animal studies support the idea that vitamin B12 concentration plays a 
critical role in stabilizing MTR activity as induced B12-deficient rats had severely 
reduced MTR activity levels compared to the enzyme activity levels of rats in a 
control group who were not B12-deficient (51).  
Homocysteine remethylation by MTR also requires 5-methylTHF as a 
substrate, which is provided by a reaction catalyzed by methylenetetrahydrofolate 
reductase (MTHFR). This key enzyme has been extensively studied in relation to 
CVD pathogenesis because MTHFR is responsible for the reduction of 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF) to 5-methylTHF, the active folate 
derivative required for homocysteine remethylation. Insufficient levels of this major 
form of folate in the human body can result in hyperhomocysteinemia (52-53). A 
single base, non-synonymous substitution of C to T at nucleotide 677 (rs1801133), 
leading to an alanine to valine amino acid substitution at codon 222, has been 
identified where a missense mutation in the region encoding the N-terminal catalytic 
domain results in a thermolabile variant with a 50% reduction in enzymatic activity 
(54-55). This variant has been consistently associated with mildly elevated plasma 
homocysteine levels (52, 56) and has been found to be more prevalent among 
individuals with CVD than those without (55, 57). Given that MTHFR 677 CT is 
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the most widely studied polymorphism in folate metabolism, we seek to understand 
how the combined effects of other polymorphisms affecting enzymes in folate 
metabolism influence the relation of MTHFR 677 CT with elevated homocysteine 
levels.  
The thermolabile MTHFR 677 CT polymorphism accounts for mild 
hyperhomocysteinemia in only about 25% of vascular disease patients (52), suggesting 
that additional mutations in the MTHFR gene, or in related genes, may contribute to 
elevated homocysteine levels. One such polymorphism found in the C-terminal 
regulatory domain of MTHFR is MTHFR 1298 AC (rs1801131), which leads to a 
glutamine to alanine amino acid substitution (54,58). Studies taking a single candidate 
gene approach have found no relation between the MTHFR 1298 AC 
polymorphism, homocysteine levels and risk for CVD (59-62). However, results from 
observational studies looking at the combined effects of MTHFR 1298 AC and 
MTHFR 677 CT have produced mixed results: several studies reported no additional 
explanatory power in MTHFR 1298 AC for predicting coronary disease outcome 
once the MTHFR 677 CT SNP was considered (59-62), but other reports suggest 
that combined heterozygosity for MTHFR 677 CT and MTHFR 1298 AC 
mutations is associated with hyperhomocysteinemia (58). More specifically, van der 
Put et al. examined the effects of MTHFR 1298 AC on homocysteine levels and 
CVD risk and demonstrated an interactive effect: individuals heterozygous for both 
MTHFR 677 CT and MTHFR 1298 AC had reduced MTHFR specific activity 
(ANOVA p<0.0001), higher homocysteine levels and decreased plasma folate levels 
(ANOVA p<0.03) (58). The effect of combined heterozygosity was also shown by 
Lievers et al. and Weisberg et al. who noted that individuals with MTHFR 677 
CT/1298 AC genotype had slightly higher homocysteine levels than those with the 
MTHFR 677 CT /1298 AA genotype (54, 63-64). When folate status was additionally 
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accounted for, Weisberg et al. found that the relation between MTHFR 1298 AC 
genotype and homocysteine levels was stronger among those with folate levels below 
the median than those with levels above the median, though the association was not 
statistically significant (data not shown in publication) (54). Finally, an in vitro study 
directly assessing the effect of MTHFR 1298 AC on enzyme activity and 
thermolability concluded that the MTHFR 677 CT variant was more deleterious 
than the alanine variant of MTHFR 1298 AC (54) , suggesting that the role of 
MTHFR 1298 AC  on MTHFR enzyme activity is minor compared to that of  
MTHFR 677 CT . Overall, the evidence to date is suggests that the effect of MTHFR 
1298 AC is not observed to have an effect on clinical outcomes unless there is a 
reduced folate status or there is also a variant allele at the 677 nucleotide (MTHFR 677 
CT). In our current study, a mathematical model including both MTHFR SNPs will 
allow for a complete examination of the MTHFR genotype combinations as they relate 
to homocysteine levels.  
In addition to genetic factors, MTHFR activity is also influenced by levels of 
folate. Epidemiology studies have found that in populations with low folate status the 
associations among the MTHFR 677 CT polymorphism, CVD risk, and elevated 
homocysteine are more pronounced (53, 65). However, when folate levels are higher, 
the net effect of the MTHFR 677 CT polymorphism on homocysteine levels is 
attenuated (65), highlighting an important gene-nutrient interaction between folate and 
MTHFR 677 CT.   
The rate of conversion of 5,10-methyleneTHF to 5-methylTHF, which is 
needed for homocysteine remethylation by MTR, is also dependent on the availability 
of 5,10-methyleneTHF. Cytosolic serine hydroxymethyltransferase (cSHMT) and 
methylenetetrahydrofolate dehydrogenase (MTHFD1) are both enzymes that catalyze 
reactions producing 5,10-methyleneTHF. Metabolic disruptions caused by changes in 
10 
activity in these enzymes make cSHMT and MTHFD1 important producers of a 
substrate that may ultimately influence homocysteine remethylation. cSHMT is a key 
enzyme responsible for regulating and maintaining the homeostasis of the intracellular 
one-carbon pool. It supplies one-carbon units for thymidylate biosynthesis, sequesters 
5-methylTHF causing reduced S-adenosylmethionine synthesis, and catalyzes glycine-
dependent serine synthesis which depletes 5,10-methyleneTHF for homocysteine 
remethylation (66).  
A SNP in cSHMT, cSHMT 1420 CT, was identified by Stover et al., and 
causes an amino acid change from leucine to phenylalanine (67-68). Recent studies 
find that cSHMT 1420 CT polymorphism (rs1979277) is located close to the 
sumoylation site on the cSHMT protein, which affects nuclear localization of the 
protein (69). Epidemiologic studies have implicated this polymorphism in a variety of 
diseases including leukemia (70) and lymphoma (71-72), esophageal squamous cell 
carcinoma and gastric cardia adenocarcinoma (73) and neural tube defects (74). 
cSHMT 1420 CT has also been investigated in relation to CVD outcome: findings 
show that the effect of MTHFR 677 CT on CVD risk is strongly influenced by 
cSHMT 1420 CT genotype. Specifically, among men with cSHMT 1420 TT 
genotype, the risk of CVD for MTHFR 677 CT and TT genotypes was 3.6 (95% CI: 
1.7,7-8) and 10.6 (95% CI: 2.5, 46.0), respectively (compared to MTHFR 677 CC 
genotype). Among men with cSHMT 1420 CC/CT genotype the risk for CVD among 
MTHFR 677 CT and TT genotypes (compared to MTHFR 677 CC) was 1.0 (95% CI: 
0.8, 1.2) and 1.3 (95% CI: 0.9, 1.8), respectively (75).  Whether this increase risk is a 
result of elevated homocysteine levels was not determined. 
This evidence suggests that the metabolic disruptions resulting from cSHMT 
1420 CT have the potential to play a role in health outcomes, particularly in CVD 
pathogenesis, through gene-gene interactions. Since the study by Lim et al. (75) found 
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an effect resulting from a pair-wise interaction between polymorphisms in cSHMT and 
MTHFR on CVD risk, it is plausible that these polymorphisms may also interact with 
SNPs in MTR or MTHFD1 from the epidemiology perspective.  Again, the 
relationship of any clinical consequence to hyperhomocysteinemia remains unknown. 
MTHFD1 is a tri-functional enzyme that catalyzes three sequential reactions 
responsible for the interconversion of 5,10-methyleneTHF and THF. A polymorphism 
in the coding region, MTHFD1 1958 GA (R653Q; rs2236225) has been implicated 
as a cause of neural tube defects (76-77), bipolar disorder and schizophrenia (78) and 
is associated with the risk for migraine and gastric cancer through an interaction with 
the MTHFR 677 CT genotype (79-80). Because MTHFD1 provides the essential 
substrate for MTHFR, mutations in the MTHFD1 gene that affect enzyme activity are 
hypothesized to influence levels of homocysteine, and consequently, CVD risk. Only 
one study has examined the effects of MTHFD1 1958 GA and MTHFR 677 CT 
on CVD risk (Raiszadeh, personal communication). Findings suggest that MTHFD1 
GA/AA (vs. MTHFD1 GG) had a statistically non-significant protective association 
with CVD risk (OR 0.8; 95% CI 0.6, 1.1), and this association was similar across 
folate subgroups. A gene-gene interaction was observed whereby an increased risk of 
CVD was found for the MTHFR 677 TT genotype (vs. MTHFR 677 CC), but only 
among men with MTHFD1 GA/AA genotype (OR 1.6, 95% CI 1.1, 2.4). Similarly, the 
MTHFR 677 CT genotype (vs. MTHFR 677 CC) increased CVD risk among men with 
MTHFD1 GA/AA genotype (OR 1.2; 95% CI 0.9, 1.7), but had little or no effect in 
men with the MTHFD1 GG genotype (OR 0.8; 95% CI 0.5, 1.3) (Raiszadeh, personal 
communication). No other study to date has examined the role of multiple 
polymorphisms that include MTHFD1 1958 GA on CVD risk by examining the 
changes in homocysteine levels. 
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Taking a new approach to understanding cardiovascular disease, the research 
presented in the following chapters examines the interactive effect of 5 SNPs in genes 
coding for enzymes in folate metabolism on CVD outcome by looking at changes in 
homocysteine steady state concentrations as a proxy (Table 1.1). To the best of our 
knowledge, no published study to date has considered more than one gene-gene 
interaction in genes within the homocysteine remethylation pathway in relation to 
CVD outcome. Moreover, the majority of studies to date have taken an epidemiologic 
approach to understanding folate metabolism and its relation to homocysteine and 
cardiovascular disease. While epidemiologic gene association studies help identify 
correlations between single genetic variables and disease outcomes, such an isolated 
approach rarely leads to the formulation of relations that can remain true when entities 
of a biological system are examined as a whole with respect to disease outcome. Thus, 
to understand how genetic polymorphisms affect enzymes in homocysteine 
remethylation as a whole, we propose a new method of analyzing biological systems 
using complex systems analysis. 
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Table 1.1: Five Gene and SNP Information 
Gene SNP Amino Acid Change MAF1 
cSHMT 
17p11.22 
1420 CT 
rs1979277 
Leu474Phe HapMap CEU: 0.333 
NAS: 0.310 
MTHFD1 
14q24 
1958 GA 
rs2236225 
Arg653Gln HapMap CEU: 0.458 
NAS: 0.465 
MTHFR 
1p36.3 
677 CT 
rs1801133 
1298 AC 
rs1801131 
Ala222Val 
 
Glu429Ala 
HapMap CEU: 0.242 
NAS: 0.363 
HapMap CEU: 0.358 
NAS: 0.306 
MTR 
1q43 
2756 AG 
rs1805087 
Asp919Gly HapMap CEU: 0.167 
NAS: 0.181 
1 Minor Allele Frequency for each of the 5 SNPs assayed in the Normative Aging 
Study population (NAS), which consists of white males with European ancestry, 
compared to the CEU reference population, which refers to the subgroup of people 
living in Utah with ancestry from northern and western Europe in the International 
Haplotype Mapping (HapMap) Project (81)   
2Chromosome location  
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B. THE ROLE OF COMPLEX SYSTEMS METHODS IN METABOLIC 
MODELING 
Systems Biology and Complex Systems Approach 
The discipline of systems biology focuses on addressing the great intellectual 
and technical challenges associated with translating genome sequence into a 
comprehensive understanding of how organisms are built and run. It is rooted in the 
idea organisms are more than the sum of their parts, and the behavior of their 
physiological processes cannot be understood by simply knowing how the parts work 
in isolation. A systems level characterization of a biological process addresses three 
fundamental questions: (i.) what are the parts of the system? (i.e., the genes and the 
enzymes and proteins that they code); (ii.) how do the parts work? (iii.) how do the 
parts work together to complete a task? (82). 
A system is a relation of items. Items within a system take on any range of 
identities including physical objects, indicators, variables or even symbols. For 
example, a genome is a set of genes and a metabolic pathway can be described by rate 
equations. In mathematical set theory, a system can be defined as the set of all ways in 
which an item Ai can be found in the system, where * denotes that all items are seen 
simultaneously. 
S ⊂A1 *A2 *…….*Ai….*.... An 
Here, an element of S represents a multiple of the elements in each of the items, s = 
(i1, …..in). Items are mutually interdependent, therefore, they constitute a relation.  
 A complex system is therefore defined by the following: (i.) the global system 
has a distinct behavior and (ii.) the subsystems within the global system preserve their 
own identities and inherent properties. Symbolically, a complex system can be 
represented as:  
S ⊂S1 *S2 *…….*Si….*.... Sn 
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In describing a complex system, “distinct” behaviors imply that the behavior of the 
complex overall system is described in terms of items (i.e., subsystems) that are 
different than the items used to describe the subsystem components. For example, 
Figure 1.3 illustrates the folate metabolic network, an entity that can be considered as 
a global system. Here, there are three subsystems that describe the global system: the 
methionine cycle, thymidylate cycle and the purine cycle. Furthermore, each 
subsystem is characterized by items such as enzyme kinetics, substrate concentration, 
product concentration and nutrient cofactor levels. Figure 1.1 illustrates the items for 
describing the methionine cycle subsystem. The items used to describe the subsystems 
that form a complex system have their own boundaries and existence, yet their 
behavior and function is conditioned by their presence within the overall global, 
complex system. Specifically, the methionine cycle, thymidylate cycle and purine 
cycle are all acknowledged as such, but their functioning and existence is conditioned 
as being part of the total system (i.e., folate metabolism). 
Principles of organized complexity 
 A major challenge that has yet to be fully addressed in systems biology is the 
development of principles of organized complexity in biological systems. These 
principles, in theory, should provide a starting framework to uncover the 
understanding of systems from observation and data. Moreover, these principles 
should indicate the functions of biological systems and/or their components. They 
provide the “architecture” of the model and may not necessarily be numerically based. 
Levels of complexity and the autonomy of levels 
The idea of multilevel-ness is an essential principle of organized complexity.  
A biological example of multilevel-ness can be seen in the study of CVD. CVD is a 
complex event that can be studied from a variety of perspectives. Genetic variables, 
small molecule and protein interactions as well as epidemiological trends are viable 
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methods of studying CVD. Each method provides a subset of information explaining 
some aspect of CVD. How all of the subsets can be combined or studied concurrently 
to provide an understanding at the global level lies at the heart of systems biology 
from a complex systems approach. The concern in systems biology and complex 
systems is, therefore, to understand how the functioning of a higher level (i.e., the 
global level) is related to the functioning on a lower level (Figure 1.4). 
 
 
 
 
 
 
 
Higher level 
 
 
 
Lower level 
 
 
 
 
 
Figure 1.4: Multilevel-ness in the study of cardiovascular disease 
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The study of complex systems is “a new field of science studying how parts of 
a system give rise to the collective behaviors of the system, and how the system 
interacts with it environment…It focuses on certain questions about parts, wholes and 
relationships…[It] is about understanding indirect effects” (83). Complex systems, 
therefore, is integrative and seeks to understand and predict the behavior or 
“emergent” properties of complex, multicomponent biological processes. Here, 
emergent is defined as the distinct behavior on a higher level that is solely due to the 
way the subsystems on the lower functioning level interact. 
As Stuart Kauffmann suggested, there are domains of autonomy on the lower 
level of subsystems that do not affect the behavior of the system at the higher level. 
The domain of autonomy is a range of changes on the lower level and the 
corresponding range of normal behavior on the higher level such that the two levels do 
not interact; the changes on the functional level are treated as “background noise” on 
the higher level (84). This brings up the need to clarify the idea of interaction and 
interdependence among levels and subsystems within a complex system, namely, that 
even though levels are interdependent in many ways, they can be viewed as non-
interacting within domains of autonomy. In the case of folate metabolism, all three 
subsystems (i.e., methionine, thymidylate and purine cycles) are all interdependent on 
each other via 5,10-methylenetetrahydrofolate. While enzymes and cofactors in each 
cycle will perturb reaction rates and equilibrium within their respective cycles, 
whether or not these perturbations of the “subsystems” are manifested in the global 
properties that drive folate metabolism is best measured using a complex systems 
approach.  
Interactions and Links 
When a system is “complex,” its subsystems and items defining each subsystem are 
interdependent and a quantifiable description of each item of varying levels requires 
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algorithmic complexity. Algorithmic complexity, is defined as the quantity of items 
needed to describe the system (or subsystem) and the number of clauses to define the 
relationships/interactions among the items is large (i.e., it cannot be described with a 
single-worded answer or using a single sentence). The descriptions for items at each 
level vary. At the higher level, the purpose is to coordinate the subsystems to perform 
work. Thus, the function of interactions at the higher level should consist of providing 
guidance or motivation for the subsystems to act so as to advance the overall system’s 
objective. It is necessary to organize the functioning of subsystems so that the overall 
system, as a whole, functions properly (84). In the case of folate metabolism, this 
means that at the higher level of complexity, the folate metabolic system, as 
represented in Figure 1.5 as CP(∆p),  is concerned with ensuring that thymidylate, 
methionine and purine cycles (Si[∆i(β)], where ∆1….∆n represent regulation 
objectives) are all operating such that folate metabolic system will continue to 
function. Coordination theory (85) suggests that coordination can affect the first level 
of subsystems (i.e., the three cycles) by an input β to modify their functioning. These 
three subsystems are, in turn, responsible for their own functions at a lower level (i.e.,  
regulating their enzymes/items) and are modified by coordination at the higher level. 
In other words, according to coordination theory, let ∆ represent the functioning of the 
system as a whole and sat∆ indicate that the functioning of the overall system is 
satisfactory. The purpose of the coordination task, ∆p, is to influence all ∆i(β) so that ∆ 
is achieved while the first level systems (i.e., the subsystems) perform their own, first 
(lower) level functions where: 
[sat∆1(β) ∩…sat∆i(β) ∩…sat∆n(β)] ∩sat∆p => sat∆. 
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Figure 1.5: Coordination by a coordination process 
Si is the first functional level subsystem; CP is the coordination process; ∆p is the 
coordination task; ∆i is the first level regulatory function; ui  is the interaction between 
subsystems; β is the coordination input 
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  Coordination is also necessary if perturbations are made to the overall system. 
Such perturbations, denoted as x, such as genetic mutations, can affect a subsystem’s 
ability to produce the correct amount and type (i.e., an enzyme) of information for the 
ideal, proper functioning of the overall system. When such a discrepancy arises, 
coordination is needed to bring equilibrium back to the coordination process and the 
system. Specifically, the coordination task, ∆p, then has a purpose to find β such that 
the following holds true: 
[sat∆1(x,β) ∩…sat∆i(x,β) ∩…sat∆n(x,β)] ∩sat∆p => sat∆. 
 Sometimes, these perturbations cannot be corrected and a system’s 
equilibrium cannot be achieved. In this case, it is thought that over time, the system 
will adapt to reach a new state of equilibrium (85). More specifically, as with many 
biological phenomena, slight perturbations (i.e., single nucleotide polymorphisms) are 
often not fatal because biological systems are robust and resilient to change. This 
suggests that even with mutations, a biological system can tolerate deviations and 
imbalances and adapt within certain bounds to continue proper function at a reduced 
level of optimization. It is of interest to determine what these bounds are and how a 
system adapts. Using complex systems analysis, the bounds of a given metabolic 
pathways and perturbations within the pathway could theoretically be examined.  
Gene-Disease Modeling: A Case for the Complex Systems Approach 
Developing a systems level understanding of a physiological process requires 
identification of the genes and the proteins that they encode (i.e., the “parts”). The 
field of functional genomics is one that has developed and utilized large-scale and 
high-throughput methodologies to define and analyze gene function by integrating 
data obtained from multiple large-scale datasets (86-91). Traditional reductionism has 
also given us a deeper understanding of the parts involved in the organizational 
structure of biological processes. It has elucidated the importance of cellular 
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components and regulatory processes of specific genes, proteins and metabolites. In a 
sense, reductionism has established the foundation upon which the behavior of 
complex physiological processes can be studied as a whole.   
As the writer Alvin Toffler once said, “One of the most highly developed skills 
in contemporary Western civilization is dissection: the split-up of problems into their 
smallest possible components. We are good at it. So good, we often forget to put the 
pieces back together again” (92). In the world of gene association studies, we see 
exactly what Toffler described, namely, we know a lot about the association of a 
single gene with a single disease outcome, but we fail to acknowledge the 
interdependency among different genes that code for enzymes and proteins that 
interact with one another (93).  
Current strategies to understand the role of genetic variation in various clinical 
phenotypes illustrates the growing need for a complex systems approach to studying 
the relationship between genetic information and human disease. Original 
methodologies designed to discover links between genetic information and human 
disease have traditionally focused on the evaluation of candidate genes identified by 
classical reductionist techniques in the laboratory (94). This methodology relies on 
existing knowledge of the genes to determine the properties of important cell systems 
presumed to be disturbed in a disease state. Additionally, candidate gene studies have 
been characterized by the examination of genetic variation in a single gene, which 
ignores the interaction between related genes coding for proteins in the same pathway. 
Because investigation tends to be limited to genes of known function that have been 
linked to the pathophysiology of a disease in question, candidate gene studies can—
and have- produced conflicting results. These inconclusive results are thought to be 
attributed to the fact that only select parts of a whole entity are studied; how can we 
possibly understand a whole system if we do not account for all of its parts? In 
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contrast, complex systems analysis would suggest that multiple genes are likely to 
play an important role in complex chronic diseases and that many “weaker” genes 
(i.e., those that may be insignificant when studied in isolation with respect to the 
disease) when combined, may actually have a contributing effect on disease risk or 
state (95).  
Research Significance and Objectives 
 The overall objective of this study is to examine the joint effect of multiple 
variants in folate metabolism on CVD outcome.  The intermediary outcome, 
homocysteine, will be investigated as the primary endpoint because the metabolic 
disruption characterized by elevated homocysteine levels is proposed to mediate the 
risk of CVD. Because epidemiologic studies are limited by small sample size, and thus 
reduced statistical power to examine genetic interactions and their combined effects on 
disease outcome, we use computer simulations to study five SNPs in four candidate 
genes that code for enzymes that are all linked through sequential metabolic steps in 
homocysteine remethylation. These enzymes are either directly involved in 
homocysteine remethylation or indirectly linked because they provide essential 
substrates required for the conversion of homocysteine to methionine by MTR. Using 
MTR as our focal point, we also considered gene-nutrient interactions among the five 
variants and varying levels of folate and vitamin B12 to account for the possible 
effects of nutritional status on disease risk. Such an approach allows for the 
consideration of multiple genotype-genotype interactions and multiple genotype-
nutrient interactions, capturing the complexity underlying the development of CVD. 
The specific research aims are as follows: 
1.) To examine the interactive effects of 5 SNPs on homocysteine levels and identify 
genetic profiles most susceptible to elevated homocysteine levels (and by extension, 
elevated risk for CVD); 
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2.) To determine how varying levels of  5-methyl-THF (folate) and vitamin B12, both 
required for MTR activity, affect homocysteine levels among the different genetic 
polymorphism combinations.  
 
24 
CHAPTER 2 
MODELING ALGORITHM AND PROGRAM 
This study utilizes mathematical modeling to understand the overall function 
of the folate metabolic network as it relates to homocysteine regulation through MTR. 
Vast amounts of scientific literature have provided extensive detail about single 
reactions and single pathways that comprise folate metabolism, but as previously 
discussed, no study has examined the overall function of homocysteine remethylation 
under the influence of multiple genetic variation and the possibility of further effects 
created by nutritional supplementation and variation. Due to limitations in statistical 
power (epidemiological studies) and levels of complexity that cannot be fully captured 
in purely experimental studies, we utilize mathematical models to study folate 
metabolism as a dynamic and complex biological system.  
Basic Mathematical Model for Homocysteine Remethylation 
To develop models of integrated biochemical processes, it is necessary to 
consider the mechanisms by which biochemical information is transferred in a 
network. In a mathematical model of folate metabolism created by Reed et al. (96), a 
model is derived using standard biochemical kinetics. It has been shown to reproduce 
both the many known properties of folate metabolism as well as the qualitative 
behaviors of the folate cycle reported in experimental studies (96-97).  
In our study, the effect of multiple SNPs on homocysteine regulation via MTR 
(highlighted subsystem in Figure 2.1) was simulated by building upon the model of 
folate metabolism originally published by Reed et al. and Nijhout et al. (96-97). While 
our research focuses primarily on the highlighted subsystem within the larger folate 
metabolic system depicted in Figure 2.1, our mathematical model incorporates both 
the folate cycle and the methionine cycle in order to account for the presence of all 
folate-derived, intracellular substrates as well as folate regulating enzymes. Due to 
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limited information on all possible SNPs in genes coding for enzymes in the folate and 
methionine cycles, we have made some parameter and substrate values constant in our 
study and have focused primarily on genetic and nutrient outcomes related to genes 
and enzymes in our highlighted subsystem of interest. The values, expressed in micro 
Molar, µM, that we have kept constant are given in Table 2.1 and are based on 
information reported in the literature.   
 
 
 
 
 
Figure 2.1: Folate and Methionine Cycle, adapted from Reed et al. (96).  
Substrates are represented by rectangular boxes, enzymes in ovals and vitamin 
cofactors in circles 
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Table 2.1: Concentrations of Substrates Used in Model that are held constant 
(units: µM) 
Substrate Concentration Reference 
glycinamide ribonucleotide [GAR] 10 98 
aminoimidazolecarboxamide 
ribonucleotide [AICAR] 
2.1 98-100 
nicotinamide adenine dinucleotide 
phosphate [NADPH] 
50 98,101 
Glycine [GLY] 1850 98,99,102 
Serine [SER] 468 98,99,102 
Betaine [BET] 50 96 
Formate [HCOOH] 500 100,102 
Formaldehyde [H2C = O] 500 96 
deoxyuridine monophosphate [dUMP] 20 98-100 
 
Our current model of the folate metabolic cycle is represented by ten 
differential equations and various enzyme velocity equations that describe folate 
substrate concentration over time. For each enzyme, the Km is given in µM and the 
Vmax and the enzyme velocities of the reactions, V, are expressed in µM/hr. The 
abbreviated notation used to describe our metabolic system is as follows: 
 
5mTHF = 5-methyltetrahydrofolate 
THF = tetrahydrofolate 
DHF = dihydrofolate 
CH2F = 5-10-methylenetetrahydrofolate 
CHF = 5-10-methenyltetrahydrofolate 
10fTHF = 10-formyltetetrahydrofolate 
MET = methionine 
SAM = S-adenosylmethionine 
SAH = S-adensylhomocysteine 
HCY = homocysteine 
Metin = influx of methionine into the system (µM/hr) 
Fin/out = influx and outflux of folate 
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Initial concentrations for all variables in our model are given in Table 2 and are 
based on steady-state values found in the literature.  
 
Table 2.2: Initial Substrate Concentrations Used in Models (units: µM) 
Substrate Concentration Reference 
MET 48 96 
SAM 64.42 96 
SAH 13.04 96 
HCY 1.11 96 
CH2F 0.90 96 
5mTHF 5.16 8,9 
THF 8.01 96 
DHF 0.03 97, 98 
CHF 1.12 96, 97 
10fTHF 5.93 98, 100, 103,104 
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Since substrate concentration dictates the velocity of reactions catalyzed by 
enzymes, the following differential equations were used to describe the change in 
substrate concentration over time: 
 
 
 
 
 
 
 
 
 
 
 
 
The velocities of the reactions for each enzyme in our model are given in Table 2.3.  
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Table 2.3: Kinetic Parameter Values Used in Model 
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Parameter Model Reference 
AICART 
      Km,s (AIRCARP) 
      Km,F (10f-THF) 
      Vmax 
 
100 
5.9 
45,000 
106-109 
 
BHMT 
      Km,F(HCY) 
      Km,S(BET) 
      Vmax 
 
12 
100 
1125 
110-112 
CBS 
      Km (HCY)       
      Vmax 
 
1000 
90,000 
113-115 
DHFR 
      Km,s (NADPH) 
      Km,F (DHF) 
      Vmax 
 
4 
0.5 
50 
106,107,97,116 
DNMT 
      Km 
      Ki 
      Vmax 
 
1.4 
0.84 
180 
117 
FTD 
      Km,F (10f-THF) 
      Vmax 
 
20 
14,000 
118 
FTS 
      Km,s (HCOOH) 
      Km,F (THF) 
      Vmax 
 
43 
3 
2000 
106,108 
GNMT 
      Km 
      Ki 
      Vmax 
 
63 
10.8 
288 
119,105, 120 
MAT-I 
      Km (MET) 
      Vmax 
 
41 
260 
121 
MAT-III 
      Km (MET) 
      Vmax 
 
300 
220 
121,122 
MTCH (reversible) 
      Km,F1 (CHF) 
      Km,F2 (10f-THF) 
      Vmax1 
      Vmax2 
 
250 
100 
800,000 
20,000 
106-109 
MTHFD1 (reversible) 
      Km,F1 (CH2F) 
 
2 
106,109,97,123 
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 Table 2.3 (Continued)    
 
Km,F2 (CHF) 
      Vmax1 
      Vmax2 
 
 
10 
200,000 
594,000 
MTHFR 
      Km, s(NADPH) 
      Km,F (5,10-CH2-THF) 
      Vmax 
 
16 
50 
5000 
124-128 
MTR 
      Km,F (5mTHF) 
      Km,F (HCY) 
      Vmax 
 
25 
0.1 
500 
129-131 
NE of THF by 1st order 
mass action 
      k1 
      k2 
 
 
0.15 
12 
132-133 
PGT 
      Km,s (GAR) 
      Km,F (10f-THF) 
      Vmax 
 
520 
4.9 
16,200 
106,107,134,135 
SAHH 
      Km (SAH) 
      Km (HCY) 
      Vmax1 
      Vmax2 
 
10 
1 
5000 
5000 
136 
SHMT (reversible) 
      Km,s1 (Serine) 
      Km,F1 (THF) 
      Km,s2(Glycine) 
      Km,F2(CH2-F) 
      Vmax1 
      Vmax2 
 
600 
50 
10,000 
3,200 
40,000 
25,000 
106-109,97,127,137-139 
TS 
      Km,dUMP 
      Km,CH2F 
      Vmax 
 
 
6.3 
14 
5000 
106,107,97,140, 141 
Time is given in hours, h, and concentrations are expressed in µM 
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Many of the velocity equations are assumed to behave dependently on their substrates 
as dictated by Michaelis-Meten kinetics (96). Thus, the rate of enzymatic activity for 
irreversible reactions (i.e., reactions catalyzed by MTR) is defined as 
 
 
 
and for reversible reactions (i.e., reactions catalyzed by MTHFD1 and cSHMT),  
 
 
 
where   S = nonfolate substrate concentration 
             F = folate substrate concentration 
 
In the global folate metabolic network-- and not in our highlighted subsystem 
of interest- the reaction between CH2F and THF that is accounted for in our model is 
non-enzymatic. Because of this we expect the reaction to follow a mass action rate law 
of pseudo first-order where k1 and k2 are rate constants:  
 
V[NE] = k1 [THF][H2C=0] - k2 [CH2F]  
The remaining velocity equations are presented individually, as they do not 
strictly adhere to general Michaelis-Menten kinetics (96); we illustrate the kinetics of 
each [enzyme] below as originally published by Reed et al. (96) such that when 
parameter values (i.e., Km and Vmax) given in Table 2.3 for respective enzymes are 
used in the equations, the kinetics are Michaelis-Menten. Concentrations of SAM and 
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SAH are included as regulatory methods (either activating or inhibiting an enzyme) 
and scaling factors are used so that the value of regulation equals 1 for our models 
since our initial methionine input rate (metin) is set at 100µmol/(L hr). The input rate 
for the starting methionine level is chosen based on the work of Storch et al. (105) 
who found that over a 24 hour period, mean methionine levels in the human liver is 
approximately 100 µmol/(L h) after accounting for fasting and feeding states during a 
typical 24 hour period. 
 
 
 
 
 
 
 
 
 
 
VሾMAT‐Iሿ  
 
 
VሾMAT‐IIIሿ	  
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Interactive Effects of Multiple Genetic Variants on Homocysteine Remethylation 
Building upon the basic folate metabolic model, we developed a mathematical 
model that accounts for the interactive effect of five unique SNPs in genes coding for 
enzymes involved in the methylation of homocysteine by MTR. The genetic effects 
resulting from each of the five SNPs are expressed with a scalar value that serves as a 
multiplier to the SNP’s corresponding enzyme velocity equation. Since a person can 
have one of any three possible genotypes for each of the five genetic polymorphisms 
(i.e., homozygous dominant, heterozygous or homozygous recessive), a total of 243 
possible genetic combinations, and subsequent graphs, are created.  Based on findings 
in the literature, the homozygous dominant genotype for each of the five SNPs is 
classified as the “wild type” genotype (142-147). Enzyme rate for individuals with the 
“wild type” genotype for a given SNP is assumed to be fully functional at 100% 
activity. To date, the exact rate of activity for each enzyme for a particular genotype, 
with the exception of MTHFR, has not been determined experimentally or published 
in the literature. Without such information, we approximate that the heterozygous and 
homozygous recessive genotypes reflect a 60% and 30% enzyme activity rate, 
respectively. These hypothesized reductions in enzyme activity rate for MTR, 
MTHFD1 and cSHMT are motivated by biological hypotheses that assume enzyme 
kinetics and the number of variant allele copies have a dose-response relationship: 
having a single variant allele corresponds to a slightly reduced enzyme activity level 
and having double variant allele copies corresponds to an even greater reduction in 
enzyme activity level. In MTHFR, the observed functional effect resulting from the 
MTHFR 677 CT polymorphism is 60% enzyme activity for heterozygotes (CT) and 
30% in homozygote variants and 90% (AC) and 68% (CC) enzyme activity for 
MTHFR 1298 AC heterozygote and homozygous variant alleles, respectively (106-
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108, 121, 123, 128, 137, 139-141, 148-153). Table 2.4 shows the full assignment of 
percentages for the SNPs.  
 
Table 2.4: List of Functional Effects on Enzyme Activity by Polymorphism  
SNP % of wild-type activity
MTHFR 677 CT 
      CC 
      CT 
      TT 
MTHFR 1298 AC 
      AA 
      AC 
      CC 
 
100 
60 
30 
 
100 
90 
68 
MTHFD1 1958 GA  
      GG 
      GA 
      AA 
 
100 
60 
30 
MTR 2756 AG       
      AA 
      AG 
      GG 
 
100 
60 
30 
cSHMT 1420 CT 
      CC 
      CT 
      TT 
 
100 
60 
30 
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The Role of Gene-Nutrient Supplementation in Homocysteine Remethylation 
 The remethylation of homocysteine through MTR involves several nutrient 
cofactors, particularly vitamin B12 and folate. To determine if nutrient levels 
influenced the relationship between genetic variation and homocysteine levels by 
effect modification, we varied the concentration of folate and vitamin B12 for each of 
the 243 genetic profiles. In our model, folate enters and leaves the cell as 5mTHF. The 
equations for Fin and Fout, both expressed in µM/hr, is: 
Fin = (Steady state folate concentration)(0.0008)/24 
Fout = α([5mTHF]) , α = 0.0013/h 
According to Nijhout et al.(97), these expressions assume that the various folate pools 
in the body are in equilibrium and that the intracellular folate pool is depleted at the 
same rate as the total body folate pool which was approximated at 0.8% per day. By 
choosing 20 µM for steady-state folate concentration, the concentrations and values of 
other folate metabolites as listed in Table 2.2 stay within ranges that have been 
observed in studies reported in the literature. Thus, when steady state folate 
concentration is set at 20 µM, Fin = 0.0067. Assuming that the output from the cytosol 
is a first order rate process at steady state, Fout  must also equal to 0.0067. The rate 
constant α is determined to be 0.0013 since the steady state concentration of 5mTHF is 
5.16 µM (Table 2.2).  
 The effects of a vitamin B12 and folate dose were achieved by applying a 
scalar multiplier of 14 to V[MTR] and 100 to V[MTHFR]. The scalar multiplier for 
vitamin B12 corresponds to the findings reported in the literature of a 14-fold increase 
in MTR activity in liver cells supplemented with vitamin B12 (97). Epidemiological 
studies have shown that high dietary folate supplementation attenuates elevated 
homocysteine levels observed among individuals with MTHFR genetic variants (154-
157). In our model, we assumed that there was a 100 fold increase in MTHFR activity 
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rate as a result of folate supplementation on a cellular level. Vitamin B12 and folate 
degradation in the body was considered to be negligible in our models because of the 
large half-life of vitamin B12 (400 days) and folate (100 days) (158,159). Since 
experimental studies have also shown that changes in MTR activity can be observed as 
early as two hours following vitamin B12 addition and that activity plateaus within 
~24-48 hours after nutritional dosing (158), our models simulate nutrient 
supplementation and its effects on homocysteine concentration and steady state 
kinetics over a 48 hour period.  
Program structure 
Our model is written in Matlab and consists of four functions: ODE, RHS, 
V_ENZYME and COMBO_EFFECT. The ODE function is responsible for solving the 
differential equations and displaying the results for homocysteine and calls 
information from the RHS function. The RHS function defines the differential 
equations in terms of enzyme velocities which are subsequently defined in the 
V_ENZYME function. In addition to the velocity equations, the V_ENZYME function 
also includes associated modifiers for the effects of the SNP combinations and vitamin 
B12. As illustrated by Figure 2.2, the first step is where the user assigns the model 
parameters. The model parameters include the initial folate and non-folate substrate 
concentrations, folate steady state influx, vitamin B12 dosage, the profile of SNP 
combinations to examine, simulated time and time step. After values for all input 
variables have been assigned and the program is initiated, the differential equations in 
RHS are initially solved from t = 0 to the first time step assigned. The resulting folate 
substrate concentrations then replace the previously assigned initial folate substrate 
concentrations and the program then undergoes another iteration, using the new folate 
concentration. This loop continues until the assigned simulated time has been reached. 
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The annotated Matlab code outlining each step needed to generate our models is found 
in Appendix A1-A4.  
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Figure 2.2: Flow chart of order of program processes 
 
 40 
CHAPTER 3 
FINDINGS AND CONCLUSIONS 
No Supplementation 
We modeled 150 scenarios for each of the 243 genotype combinations possible 
among our five single nucleotide polymorphisms of interest. For each of the 243 
genotype profiles, we computed mean homocysteine levels (µM).  
Lowest homocysteine concentration 
Without any nutrient supplementation, our simulations suggest that individuals 
with the MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA and 
cSHMT 1420 TT genotypes have the lowest concentration of homocysteine (4.5µM). 
In this genotype, only the MTHFR gene carries the mutated genotypes, MTHFR 677 
TT and MTHFR 1298 CC, resulting in decreased function. The remaining enzymes are 
functioning at full capacity in this model, with the exception of cSHMT. 
The consequence of this genotype appears to be that: 
1. Adequate substrate is delivered to MTHFR through the optimal action of 
MTHFD1; 
2. With no mutation observed in the MTR 2756 AG gene, MTR is able to 
remove all 5-methylTHF substrate, driving the reactions of the homocysteine 
remethylation cycle in the forward direction. 
3. Because the products of MTHFR activity are quickly removed from the 
system, while at the same time there is a relative glut of products from 
MTHFD1 action, the reaction pathway for MTHFR  MTR is not reversed to 
favor the buildup of 5,10-methyleneTHF. 
As a result, homocysteine is methylated efficiently in this scenario.  
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Previous single gene studies of the MTHFR 677 CT mutation have yielded 
equivocal results with respect to homocysteine status. The mechanism presented here 
may explain the lack of positive findings (i.e., elevated homocysteine levels) in the 
presence of the MTHFR polymorphism. It should be noted that there may be a 
publication bias in that negative results with this polymorphism may be discounted, as 
a simplistic consideration of this pathway would suggest that a polymorphism in the 
MTHFR gene would yield a positive result.   
Highest homocysteine concentration 
Simulation results show that among all possible 243 genotype profiles, the 
genotype group with the highest homocysteine concentration (11.9 µM) has the 
following profile: MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 
GG and cSHMT 1420 CC. 
With reduced function in MTHFD1 due to polymorphisms in MTHFD1 1958 
GA, the generation of 5,10-methyleneTHF is decreased, leaving only a small pool 
of substrate available for MTHFR to catalyze the reaction to make 5-methylTHF for 
MTR use. With diminished substrate levels for MTR due to polymorphisms in the 
MTHFD1 1958 GA and MTHFR 677 CT genes, normal MTR function is 
reduced, leading a build-up of homocysteine levels. The addition of a polymorphism 
in MTR 2756 AG, causing reduced MTR activity would therefore lead to an even 
greater increase in homocysteine concentration, which is what we observed in our 
highest homocysteine group.  
This result is not surprising, given that the series of mutations in the first 4 
enzymes would be expected to decrease the delivery of single carbon moieties to 
homocysteine. This is an example of where the mutation of the MTHFR enzyme was 
associated with elevated homocysteine levels, in contrast with the previous model, and 
in synch with expectations. Taken together these examples illustrate the importance of 
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modeling a complete set of gene-gene interaction rather than relying on single gene 
studies.   
The model with all the mutated polymorphisms, including MTHFR 1298 CC 
yields a low homocysteine level (5.8µM). It seems at first surprising that the genotype 
with every possible mutation in every enzyme would result in low rather than high 
levels of homocysteine. However it is clear from the examples given above that it is 
not the presence of mutations per se that influence homocysteine levels, but rather an 
imbalance in the activities of MTHFR vis-à-vis the remaining enzymes. The MTHFR 
1298 CC mutation debilitates this enzyme even further, with the consequence that, 
relatively speaking it is more inefficient than the other enzymes. This increased 
inefficiency results in a pattern of relative function that is virtually the same as the 
pattern where only the MTHFR gene carries the mutation. As we saw earlier, this 
pattern yields a low level of homocysteine. 
 It is clear then, that MTHFR serves as a regulator for determining whether the 
single-carbon units are passed either to the methionine regeneration pathway or to the 
thymidylate pathway. Contrary to what may be expected a priori, in this model a 
polymorphism in the MTHFR gene without polymorphisms in the other enzymes, or a 
double polymorphism in MTHFR coupled with polymorphisms in the other enzymes, 
actually leads to a better balance between substrate and product than does a lack of 
MTHFR polymorphism. The explanation for this finding lies in the fact that, as the 
model was constructed, the MTHFR enzyme can catalyze the reaction in both 
directions, towards MTR and towards the thymidylate pathway. By slowing down 
throughput towards the MTR pathway with a MTR function high relative to MTHFR, 
MTHFR has to function unidirectionally, that is, towards the production of 
methionine. 
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Finally, an in vitro study directly assessing the effect of MTHFR 1298 AC 
on enzyme activity and thermolability concluded that the MTHFR 677 CT variant 
was more deleterious than the alanine variant of MTHFR 1298 AC (54), suggesting 
that the role of MTHFR 1298 AC on MTHFR enzyme activity is minor compared to 
that of MTHFR 677 CT. Overall, the evidence to date is suggests that the effect of 
MTHFR 1298 AC is not observed to have an effect on clinical outcomes unless 
there is a reduced folate status or there is also a variant allele at the 677 nucleotide 
(MTHFR 677 CT). 
Effect of folate supplementation 
The addition of folate into the system has no effect on homocysteine levels. 
Because folate acts at each point in these pathways, its levels cannot alter the balance 
in the pathways caused by the presence or absence of polymorphisms. The model as 
constructed assumes normal levels of folate in the unsupplemented condition. To see 
any effect of additional folate on these pathways, it would be important to run the 
model under folate-deficient conditions. 
Effect of vitamin B12 supplementation 
By contrast with folate, vitamin B12 occurs at only one point in the 
homocysteine remethylation pathway, namely at the level of MTR. In this model, 
vitamin B12 was designed to increase the activity of MTR. Any increase in MTR 
activity would be expected to accelerate the transfer of single carbon moieties to 
homocysteine, thus decreasing homocysteine levels. This is indeed what was found for 
each of the genotypes (Appendix A5). However, vitamin B12 cannot, at least in this 
model system, bring homocysteine levels down to normal.  
Limitations of the study 
The models in this study are constructed to simulate the effects of mutations on 
enzyme activity by changing enzyme kinetic rates. Except for MTFHR 677 CT, we 
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have assumed that mutations have a dose-response effect on enzyme availability and 
overall activity levels. The true effects of the MTR, cSHMT and MTHFD1 
polymorphisms could be better represented in our models if such specific information 
on their effects were known. However, our models are created in such a way that they 
can be updated when new information on mutational effects become available. 
Our models do not account for other linked cycles in the folate metabolic 
network. We have focused solely on the homocysteine remethylation pathway. The 
overall cellular folate concentrations of our current model may not fully predict the 
function of a given pathway since folate metabolism can be compartmentalized in the 
cell by substrate channeling through linked cycles such as those for purine or 
thymidylate syntheses.  
We focused only on folate and vitamin B12 supplementation in our models. 
Our simulations assumed that no nutritional deficiency existed before 
supplementation. Differences in homocysteine levels among those with low nutrient 
status were not explored and could possibly be useful for better understanding the 
interaction of vitamin cofactors with their respective enzymes. 
Conclusions and suggestions for further research 
By examining homocysteine remethylation as a complete pathway, our 
mathematical models were able to capture the combined effects of linked metabolic 
steps on homocysteine concentration. This approach led to the key finding that having 
double variants for all possible polymorphisms in a pathway does not necessarily 
equate to the most deleterious effects. It also illustrates how pathways have built-in 
regulatory mechanisms that researchers might not be able to account for when taking a 
single candidate gene approach to studying disease outcome.  
A key advantage of our simulations is that they provide for quick and easy 
investigation of variation in multiple inputs (i.e., gene-gene and gene-nutrient 
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interactions) that cannot be explored in traditional epidemiology studies. Our models 
can account for an unlimited number of variables and can be expanded to represent 
larger metabolic networks. Future research can expand upon the work presented by 
linking other metabolic cycles that are associated with substrates or enzymes already 
found in homocysteine remethylation (i.e., purine or thymidylate syntheses). 
Additionally, research can be done to understand how equilibrium is attained by 
certain genotype combinations. This could also be expanded by seeing how nutrient 
supplementation further modifies how steady state is achieved. 
In conclusion, our mathematical modeling of homocysteine remethylation 
provides a new tool for investigating the effects of genetic variation and nutrient 
effects in one carbon metabolism. We anticipate that our model will serve as an 
example of how simulations can help advance the growing idea that disease treatment 
can be personalized by examining an individual’s unique genetic and nutritional 
profile.  
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APPENDIX  
A1: ODE Annotated Matlab Program 
1  %This program models the folate and methionine cycle. 
2    
3  %Modifiable settings are the following: 
4  %(1) The set of SNP combos one wishes to model.  
5  %This is under the ODE function under the variable  
6  %s at line 42. 
7 
8  %(2) Length of time to simulate. This is under the  
9  %"tend" variable under the ODE Function at line 57.  
10  %The units are in hours. In addition, one can also  
11  %change how many steps the program takes to get from  
12  %t=0 to t=tend. 
13 
14  %(3) Initial folate concentration. It is under the  
15  %RHS function at line 34.  For our model, the  
16  %default is 100uM. 
17 
18  %(4) The rate of methionine into the system  
19  %(to simulate met loading). This is found in  
20  %the RHS function at line 33. Units are uM/hr. 
21 
22  %(5) Vitamin B12 supplementation. When there is  
23  %supplementation, 3689uM of  B12 is added into the  
24  %system. This is done by manipulating the variable  
25  %"Vitamin_Dose" in the Enzyme function at line 21.  
26  %Just change the value to equal 1 for B12 loading  
27  %or 0 for no loading.  
28 
29  clear global s; 
30  clf('reset'); 
31  tic 
32      global s;  
33      %sets s as a global variable. This variable is  
34      %used in the “Combo_Effect” function 
35      HCY=zeros(121,6); 
36      THF=zeros(121,6); 
37      %Line 35 and 36 declares two empty 101x6    
38      %matrices named HCY and THF that the following  
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39      %code will fill with data points 
40      HCY_col=1; 
41      THF_col=1; 
42          for s = (1:6);  
43           %This here starts the for loop that causes  
44           %the program to go through SNP combos 1-6.  
45           %“for s= (1:6) means “for s (the row of  
46           % vectors of the combination matrix)=1  
47           %through 6. To change the %set to 7-12,just  
48           %set s equal to "7:12" instead of "1:6".  
49       
50              values0= [5.16, 8.01, 0.03, 0.90, 1.12,  
51                        5.93, 48, 64.42, 13.04, 1.11]; 
52  %These are the initial folate substrate  
53  %concentrations in uM in the order: 
54             %[5mTHF, THF, DHF, CH2F, CHF, 10fTHF, MET,  
55               SAM, SAH, HCY, HCY]  
56                   
57              tend= 0.5; 
58              %tend is the total time in hours that we  
59               are modeling over 
60               
61              tspan=[0:tend/120:tend]; 
62              %tspan defines the time interval that  
63              %will be modeled, as well as how many  
64              %time steps will be taken. It is 
65               currently set to start at O hour and go  
66               to tend hours at tend/120 time steps 
67 
68              options = odeset('NonNegative', [1:6]); 
69              %Here we're setting some parameters for  
70              %our ode solver. Note -- NonNegative  
71              %means that whenever the solution  
72              %approaches zero, MatLab will be extra  
73              careful in choosing the next time step  
74              for solving the ODE 
75 
76              [T,X] = ode45(@RHS,tspan,values0,options); 
77              %This is where we call the ordinary  
78              %differential equation (ODE) solver. The 
79              %differential equations are called from  
80              %the RHS function and are solved with the  
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81              %initial values, values0, as well as,  
82              %with respect (wrt) to the options  
83              %defined in line 51 The solutions are  
84              %then stored in the matrix X 
85 
86              HCY(:,HCY_col)=X(:,end);  
87              THF(:,THF_col)=X(:,2); 
88              %Line 86 assigns the s column vector of  
89              %HCY to equal the end column vector  
90              %(the tenth one in this case) of matrix X 
91              HCY_col=HCY_col+1; 
92              THF_col=HCY_col+1; 
93              %Line 91 and 92 tell the code to record  
94              %the values in the next column to the  
95              %right 
96          end 
97 
98  %In Summary, lines 42-92 define what the ODE function  
99  %does for each SNP %combination that is defined in the  
100  %“for s=” statement of line 42. In this annotated code,  
101  %the ODE function would run 6 times because there  
102  %are 1:6 combination codes that have been defined  
103  %by the user.  
104 
105              plot(T,HCY(:,1),'-or') 
106              %Line 105 plots the 1st column vector of  
107              %matrix HCY.  
108              hold all 
109              plot(T,HCY(:,2),'-+g') 
110              plot(T,HCY(:,3),'-*b') 
111              plot(T,HCY(:,4),'-vc') 
112              plot(T,HCY(:,5),'-sk') 
113              plot(T,HCY(:,6),'-om') 
114              hleg = legend('1','2','3','4','5','6',  
115                     'Location','NorthEastOutside'); 
116              %Line 114 fills out the legend of the plot. 
117              % The key for whatthese numbers mean are  
118              %in the “Combo_Effect” function. The  
119              %legend has to be changed manually every  
120              %time to move from one set of 5 SNP  
121              %combinations to another. 
122              xlabel('hours'); 
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123              ylabel('[HCY]uM'); 
124              HCY 
125              THF 
126              %Lines 124-125 print out the values for  
127              %each data point. Each  column maps to a 
128      %graph. Thus, the 1st column is the top  
129              %graph on the legend.  
130 
131              str = sprintf('SetX_noB12_folate 20') 
132  %Line 131 prints out which set is currently  
133  %being modeled. It serves as a manual and  
134  %internal check; each time the user runs 
135  % the simulation, the value within sprintf()  
136  %should be manually changed so when the output  
137  %is displayed in Matlab, the combination and 
138  %modifiers used are also displayed and  
139  %cross-referenced.  
140  toc  
141  %the tic toc command in this function directs  
142  %the program to report the total time it  
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A2: RHS Annotated Matlab Program 
1  function xdot = RHS(t,x) 
2 
3  %The RHS function is where all of the ODEs that are  
4  %solved in the “ODE function” are defined. 
5    
6  Polymorphism_effect= Combo(1); 
7  %Line 6 creates the variable “Polymorphism_effect”  
8  %which stores the data called from combo(1).  
9  %Combo(1) is an address that is specific to a SNP  
10  %combination found in the “Combo_Effect” function. 
11  %The address function is necessary when calling  
12  %numbers from a separate function. The 1 in the  
13  %parenthesis is just a placeholder for calling the 
14  %data from the “Combo_Effect” function, so it can  
15  %take on any value defined in “Combo_effect”.  
16 
17  Velocity = Enzyme(x,Polymorphism_effect); 
18  %To solve the differential equations, the velocity  
19  %values for each enzyme in %the system must be called 
20  %in. Line 17 calls in the “V_Enzyme” function with  
21  %the parameters x and Polymorphism_effect, where x  
22  %is our initial folate and methionine substrate  
23  %concentrations for the first run through of the  
24  %folate %and methionine cycle. With each subsequent  
25  %iteration, x changes its value to the new resulting  
26  %concentration of folate and methionine substrates.  
27 
28  %SETTINGS ARE HERE 
29    
30  %The influx of methionine (uM/hr) and folate (uM/hr) 
31  %into the cycle can be modified in lines 27 and 28,  
32  %respectively.  
33  Metin = 0; 
34  Folate_in = 100; 
35    
36  %In the following code, xdot refers to  
37  %d[substrate concentration]/dt 
38 
39  xdot=zeros(10,1); 
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40 
41  % 5mTHF 
42  xdot(1)= Velocity(1)-Velocity(7) +  
43           ((Folate_in*0.008)/24) - (0.0013*x(1)); 
44    
45  % THF 
46  xdot(2)= Velocity(7)-Velocity(5)+Velocity(3)+ 
47           Velocity(4)+Velocity(2)-Velocity(8)- 
48           Velocity(11)+Velocity(6); 
49 
50  % DHF 
51  xdot(3)= Velocity(12)-Velocity(2); 
52    
53  % CH2F 
54  xdot(4)= Velocity(8)+Velocity(11)-Velocity(12)- 
55           Velocity(9)-Velocity(1); 
56 
57  % CHF 
58  xdot(5)= Velocity(9)-Velocity(10); 
59    
60  % 10fTHF 
61  xdot(6)= Velocity(10)+Velocity(5)-Velocity(3)- 
62           Velocity(4)-Velocity(6); 
63 
64  % MET 
65  xdot(7)= Velocity(18)+Velocity(7)+Metin - 
66           Velocity(13)-Velocity(14); 
67 
68  % SAM 
69  xdot(8)= Velocity(13)+Velocity(14)-Velocity(15)- 
70           Velocity(17); 
71 
72  % SAH 
73  xdot(9)= Velocity(15)+Velocity(17)-Velocity(19); 
74    
75  % HCY 
76  xdot(10)= Velocity(19)-Velocity(16)-Velocity(18)-  
77            Velocity(7); 
78  end 
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A3: V_Enzyme Annotated Matlab Program 
1  function V_Enzyme = Enzyme(x,y) 
2  %This function defines all of the values used in  
3  %the RHS function where the ODEs are stored. It  
4  %also takes into account the modifying elements  
5  %for the different SNP combinations from the  
6  %“Combo_Effect” function. The %parameters in the 
7  %parentheses, x and y, represent the folate  
8  %substrate concentration and the SNP modifiers,  
9  %respectively.   
10    
11      Vmax = [5000, 5000, 16200, 45000, 3000, 3300,  
12              500, 40000, 25000, 200000, 594000,  
13              800000, 20000,5000, 260, 220, 288, 
14              90000, 180, 1125, 5000, 5000];  
15 
16      %Vmax is the Michaelis-Menten enzyme kinetic  
17      %parameter. Time is in hours, concentrations are  
18      %in uM and the numbers are in the order used for  
19      %the respective enzymes in the equations below: 
20             
21      Vitamin_Dose = 0;  
22      %The user can choose to modify whether or not  
23      %supplementation by changing the value following  
24      %“vitamin_dose=”. Vitamin_Dose can take a binary 
25      %value of either 0 or 1 where 0 means there is  
26      %no vitamin B12 supplementation and 1 means there 
27      % is vitamin B12 supplementation. When there is  
28      %vitamin B12 supplementation, 3689uM of vitamin  
29      %B12 is added to the system. This value is  
30      %selected for the concentration of vitamin B12  
31      %supplementation because the DRI  states that  
32      %normal B12 absorption rate and reabsorption  
33      %rate is   0.1% per day and 3689 uM is the  
34      %highest amount of vitamin B12 that can be added  
35      %to a system depleted of vitamin B12 before 
36      %vitamin B12 retention occurs (i.e. flux in does  
37      %not equal flux out when B12 concentration is  
38      %greater than 3689uM). 
39 
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40      Vitamin_Effect = 0; 
41      %The value for Vitamin_Effect is dependent on  
42      %the value assigned for Vitamin_Dose. If there  
43      %is vitamin B12 supplementation (Vitamin_Dose=1) 
44      %, the literature states that the effect of the  
45      %supplementation on MTR activity increases by a  
46      %factor of 14 (lines 52-53). If there is no  
47      %supplementation then Vitamin_Effect=1 because 
48      %MTR activity stays the same as if a person has  
49      %their steady state concentration of 
50      %vitamin B12 (line 55).   
51 
52      if Vitamin_Dose == 1 
53          Vitamin_Effect = 14; 
54      else  
55          Vitamin_Effect = 1; 
56      End 
57 
58        
59      nf_pool = [10, 2.1, 50, 1850, 468, 50, 500,  
60                 500, 20, Vitamin_Effect]; 
61 
62      %nf_pool is a list of non-folate derived  
63      %substrates that are present in our system. In  
64      %our simulations, these values are kept constant 
65      %and the constants are steady state 
66      %concentrations in uM. Theoretically, these   
67      %values can be modified, but they are not for the 
68      % purposes of this model.order:GAR, AIRCAR,  
69      %NADPH, GLY, SER, BET, HCOOH, H2C=O, DUMP,  
70      %Vitamin B_Effect 
71       
72      V_Enzyme = zeros(19,1); 
73      %Line 72 declares a matrix V_Enzyme with the  
74      %zero matrix that has 19 rows and 1 column 
75       
76      %All 19 of these equations below were defined  
77      %by Reed et al. The equations all follow  
78      %Michaelis-Menten kinetics. 
79      %Order: 
80      %(1)MTHFR, (2)DHFR, (3)PGT, (4)AICART, (5)FTS,  
81      %(6)FTD, (7)MS, (8)SHMT, (9)MTD, (10)MTCH,  
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82      %(11)NE, (12)TS,(13)MAT-I, (14)MAT-II, (15)GNMT,  
83      %(16)CBS, (17)DNMT, (18)BHMT,(19)SAHH 
84 
85  %Below are the rate reactions for the enzymes listed  
86  %in lines 80-83). 
87      V_Enzyme(1)= y(1)*(Vmax(1)* 
88      ((nf_pool(3)/(16+nf_pool(3)))*((x(4)/(50+x(4))))) 
89      *(6.1/(10+x(8)-x(9)))); 
90      %Recall that “y” was our input from the SNP  
91      %modifier (see annotation for line 1 of V_Enzyme 
92      % function). Here is where “y” does the  
93      %modification. 
94      % y(1) defines the first element in the row  
95      %vector  
96      %y that is sent over to this function.  
97 
98      V_Enzyme(2)= Vmax(2)*((nf_pool(3)/(4+nf_pool(3))) 
99                   *((x(3)/(0.5+x(3))))); 
100      V_Enzyme(3)= Vmax(3)*((nf_pool(1)/ 
101                   (520+nf_pool(1)))*((x(6)/ 
102                   (4.9+x(6))))); 
103      V_Enzyme(4)= Vmax(4)*((nf_pool(2)/ 
104                   (100+nf_pool(2)))*((x(6)/ 
105                   (5.9+x(6))))); 
106      V_Enzyme(5)= Vmax(5)*((nf_pool(7)/ 
107                   (43+nf_pool(7)))*((x(2)/ 
108                   (10+x(2))))); 
109      V_Enzyme(6)= Vmax(6)*((x(6)/(0.9+x(6)))); 
110      V_Enzyme(7)= Vitamin_Effect*(y(3)*((Vmax(7) 
111                   *((x(10))/(0.1+x(10)))) 
112                   *((x(1)/(25+x(1)))))); 
113      V_Enzyme(8)= y(4)*((Vmax(8)*((nf_pool(5)/ 
114                   ((600+nf_pool(5))))*((x(2)/ 
115                   (50+x(2))))))-(Vmax(9)*((nf_pool(4)) 
116                   /(10000+nf_pool(4)))*((x(4))/ 
117                   (3200+x(4))))); 
118      V_Enzyme(9)= y(2)*((Vmax(10)*((x(4)/(2+x(4)))))- 
119                   (Vmax(11)*(x(5)/(10+x(5))))); 
120      V_Enzyme(10)= (Vmax(12)*((x(5)/(250+x(5)))))- 
121                    (Vmax(13)*(x(6)/(100+x(6)))); 
122      V_Enzyme(11)= 0.15*x(2)*nf_pool(7)-12*x(4); 
123      V_Enzyme(12)= Vmax(14)*((nf_pool(9)/ 
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124                    (6.3+nf_pool(9)))*((x(4)/(14+ 
125                    x(4))))); 
126      V_Enzyme(13)= Vmax(15)*((x(7)/(41+x(7))))* 
127                    (0.23+(0.8*exp(-0.026*x(8)))); 
128      V_Enzyme(14)= Vmax(16)*(((x(7)^1.21)/(300+ 
129                    (x(7)^1.21))))*(1+((7.2*(x(8)^2))/ 
130                    ((360^2)+(x(8)^2)))); 
131      V_Enzyme(15)= Vmax(17)*((x(8)/(63+x(8)))) 
132                    *(1/(1+(x(9)/10.8)))*(4.38/ 
133                    (0.35+x(1))); 
134      V_Enzyme(16)= Vmax(18)*((x(10)/(1000+x(10))))* 
135                    (((1.2*x(8))+(x(9)^2))/((30^2)+ 
136                    (x(8)+x(9))^2)); 
137      V_Enzyme(17)= Vmax(19)*((x(8))/(1.4*(1+(x(9)/ 
138                    1.4)+x(8)))); 
139      V_Enzyme(18)= exp(-0.0021*(x(8)+x(9))*(0.0021* 
140                    77.2))*Vmax(20)*((x(10)*nf_pool(6)) 
141                    /((12+x(10))*(100+nf_pool(6)))); 
142      V_Enzyme(19)= Vmax(21)*(x(9)/(10+x(9)))-Vmax(22) 
143                    *(x(10)/(1+x(10))); 
144       
145      V_Enzyme; 
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A4: Combo_Effect Annotated Matlab Program 
1  function combo_effect = Combo(z) 
2  %This function serves two purposes, to generate all 
3  %of the SNP combinations and to assign the  
4  %respective modifiers 
5 
6  global s; 
7  %Line 6 refers to the global variable, s, that  
8  %is originally defined in the %“ODE” function. 
9    
10  n=s; 
11  %Line 10 declares and defines a variable, n, to  
12  %equal whatever s is atthe time. So first run  
13  %through, s=n=1. Second run through, s=n=2, etc. 
14    
15  MTHFR = [1 2 3 4 5 6]; 
16  %Line 15 refers to the C667T polymorphism.   
17  %Number 1 = Homozygous dominant CC, 
18  %2 =Heterozygous CT, 3 = Homozygous recessive TT.  
19  %4-6 refer to the A1298C  
20  %polymorphism. Number 4 = Homozygous dominant AA,  
21  %5 =Heterozygous AC, 6 = %Homozygous recessive CC. 
22 
23  MTD = [7 8 9]; 
24  %Number 1 = Homozygous dominant GG,  
25  %2 =Heterozygous GA,  3 = Homozygous recessive AA. 
26 
27  MS = [10 11 12]; 
28  %Number 1 = Homozygous dominant AA, 
29  %2 =Heterozygous AG, 3 = Homozygous recessive GG. 
30 
31  SHMT = [13 14 15]; 
32  %Number 1 = Homozygous dominant CC,  
33  %2 =Heterozygous CT, 3 = Homozygous recessive TT. 
34 
35  sets = {MTHFR, MTD, MS, SHMT}; 
36  %Line 35 combines all of the genotypes 
37  %mentioned in lines 23-33 into a single matrix 
38    
39  [w x y z] = ndgrid(sets{:}); 
40  %Line 39 uses the ndgrid command to generate  
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41  %all the possible combinations of SNPs 
42    
43  combo = [w(:) x(:) y(:) z(:)]; 
44  %Line 43 defines matrix "combo" to be the  
45  %result of the line 31 
46 
47  selected_combo = combo (n,:); 
48  %Line 47 selects the row vector n in the matrix  
49  %"combo". Recall that n is equal to the global  
50  %variable s. Currently, for every cycle, s increases 
51  %by 1, thus for every cycle, the code will select  
52  %the next SNP combo in the %matrix "combo". In other  
53  %words, the code will move down to the next row in  
54  %the matrix. 
55 
56  %MTHFR Polymorphisms 
57  if selected_combo(1) == 1 
58         selected_combo(1) = 1; 
59      elseif selected_combo(1) == 2 
60           selected_combo(1)=0.6; 
61      elseif selected_combo(1)==3 
62           selected_combo(1)=0.3; 
63      elseif selected_combo(1)==4 
64           selected_combo(1)=1; 
65      elseif selected_combo(1)==5 
66           selected_combo(1)=0.9; 
67  else 
68          selected_combo(1)=0.68; 
69  end 
70  %In this if-statement, the appropriate modifiers are 
71  %applied to the corresponding SNP combination. 
72  %In matrix "combo", the entire first column refers  
73  %to MTHFR. For example, if a row, say [2 8 11 15],  
74  %2 would refer to the polymorphism of MTHFR c667t.  
75  %Specifically the heterozygousgenotype MTHFR 677 CT.  
76  %Following the code from line 52, the program checks  
77  %if the first element in the selected SNP combo is  
78  %equal to 1. If element is equal to 1, then the  
79  %value remains 1. Else, if the first element is  
80  %equal to 2, then the first element is changed from  
81  %2 to 0.6. This continues down the entire  
82  %if-statement. These decimal numbers representthe 
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83  % percent change in activity of the corresponding  
84  %enzyme due to thepolymorphism. In thisexample,  
85  %the heterozygous MTHFR 677 CT polymorphism  
86  %causes MTHFR to perform at 60% of its optimal  
87  %efficiency (value is literature based).  
88 
89  %MTD Polymorphisms 
90  if selected_combo(2) == 7 
91      selected_combo(2) = 1; 
92      elseif selected_combo(2)==8 
93          selected_combo(2)=0.6; 
94  else  
95          selected_combo(2)=0.3;  
96  %where selected_combo(2)==9 
97  end  
98    
99    
100  %MS Polymorphisms 
101  if selected_combo(3) == 10 
102      selected_combo(3)=1; 
103      elseif selected_combo(3)== 11 
104          selected_combo(3)=0.6; 
105  else  
106      selected_combo(3)=0.3;  
107  %where selected_combo(3)==12 
108  end  
109    
110  %SHMT Polymorphisms 
111  if selected_combo(4) == 13 
112      selected_combo(4)=1; 
113      elseif selected_combo(4)== 14 
114          selected_combo(4)=0.6; 
115  else  
116      selected_combo(4)=0.3;  
117  %where selected_combo(4)==15 
118  end  
119    
120  combo_effect=selected_combo; 
121    
122  %[A,B] = size(combo) 
123  %line 122, commented out, gives the size of matrix  
124  combo. 
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A5: Simulation Results for All Polymorphism and Nutrients 
 The following graphs depict the simulation results from running the 
homocysteine remethylation pathway model described in Chapter 2 for all 243 
possible genotypes. The graphs reflect the change in homocysteine concentration over 
a two day period with no supplementation (red), folate only supplementation (blue), 
vitamin B12 only supplementation (green) and both folate and vitamin B12 
supplementation (black).  
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MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
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MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 62 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 63 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 64 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 65 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 66 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 67 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 68 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC 
 69 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 70 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 71 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 72 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 73 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 74 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 75 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 76 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 77 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 78 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 79 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 80 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 81 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 82 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 83 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 84 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 85 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 86 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC 
 87 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 88 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 89 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 90 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 91 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 92 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 93 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 94 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 95 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC 
 96 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 97 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 98 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 99 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 100 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 101 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 102 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 103 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 104 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT 
 105 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 106 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 107 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 108 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 109 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 110 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 111 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 112 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 113 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT 
 114 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 115 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 116 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 117 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 118 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 119 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 120 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 121 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 122 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT 
 123 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 124 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 125 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 126 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 127 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 128 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 129 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 130 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 131 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT 
 132 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 133 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 134 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 135 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 136 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 137 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 138 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 139 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 140 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT 
 141 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 142 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 143 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 144 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 145 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 146 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 147 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 148 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 149 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT 
 150 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 151 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 152 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 153 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 154 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 155 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 156 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 157 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 158 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT 
 159 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 160 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 161 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 162 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 163 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 164 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 165 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 166 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 167 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT 
 168 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 169 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 170 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 171 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 172 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 173 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 174 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 175 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 176 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT 
 177 
 
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 178 
 
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 179 
 
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 180 
 
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 181 
 
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT 
 
 182 
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